New oral drug enlicitide cuts LDL cholesterol by 60%, matching injectable therapies

A new oral cholesterol drug called enlicitide reduced LDL levels by approximately 60 percent in a large-scale clinical trial, producing results that put it in the same performance range as injectable PCSK9 inhibitors like evolocumab and alirocumab. The difference is that enlicitide is a pill. That single fact changes the conversation around who can realistically use it and how consistently they will.

Injectable PCSK9 inhibitors have been available since 2015 and are highly effective, typically reducing LDL by 50 to 60 percent on top of statin therapy. The problem has always been uptake. Self-injection is a barrier for many patients, insurance prior authorization requirements are burdensome, and the drugs have historically been expensive. A decade after approval, PCSK9 inhibitors are still underused relative to the cardiovascular risk population that would benefit from them. Enlicitide, if it clears regulatory review, changes that access equation substantially.

How enlicitide works and what makes it different

Enlicitide is a PCSK9 inhibitor, meaning it targets the same biological pathway as the injectable drugs that have dominated high-intensity cholesterol treatment for the past decade. PCSK9 is a protein that reduces the liver's ability to clear LDL from the bloodstream by degrading the receptors responsible for that clearance. Blocking PCSK9 preserves those receptors and allows the liver to remove more LDL from circulation.

The challenge with oral PCSK9 inhibitors has been delivery. Earlier attempts at oral formulations failed because the molecules were too large to survive digestion and reach systemic circulation in sufficient concentrations to be effective. Enlicitide uses a peptide-based structure that the developers engineered to withstand stomach acid and intestinal degradation well enough to achieve therapeutic blood levels after oral dosing. The clinical trial results suggest that engineering approach worked.

The clinical trial data

The trial enrolled patients with elevated LDL who were already on statin therapy and assessed multiple doses of enlicitide against placebo over a 12-week primary endpoint period. The highest-performing dose cohort showed mean LDL reductions of 60.7 percent from baseline, compared to a 1.4 percent change in the placebo group. Secondary endpoints including apolipoprotein B and non-HDL cholesterol also showed statistically significant reductions consistent with the LDL findings.

The trial was not designed or powered to measure cardiovascular outcomes directly, such as heart attack or stroke rates. That is a standard limitation of phase two trials, which focus on efficacy and safety signals rather than long-term clinical endpoints. For regulatory approval and eventual clinical adoption, a cardiovascular outcomes trial would likely be needed to demonstrate that the LDL reductions translate into reduced event rates, which is the standard the FDA and cardiology professional societies apply to this drug class.

Safety profile from the trial

The trial reported that enlicitide was generally well tolerated at the doses studied. The most common adverse events were gastrointestinal, including nausea and mild abdominal discomfort, which occurred at higher rates in the enlicitide groups than in placebo but resolved without discontinuation in most cases. Liver enzyme elevations were monitored closely given the drug's hepatic mechanism and did not reach clinically significant levels in the trial population.

Serious adverse events were reported at similar rates between the enlicitide and placebo groups, with no drug-related serious events identified in the primary analysis. The developers will need longer-term safety data before regulators would consider approval, and any phase three program will likely include extended follow-up periods specifically to capture safety signals that do not appear in 12-week trials.

Why adherence is the real argument for an oral option

The clinical case for enlicitide rests as much on adherence as on efficacy numbers. A drug that reduces LDL by 60 percent in a controlled trial is only useful to the extent that patients actually take it consistently over years. Injectable PCSK9 inhibitors require biweekly or monthly self-injection, which is a significant practical barrier for patients managing multiple medications, those with needle anxiety, and those without the dexterity or caregiver support to self-inject reliably.

Research published in the Journal of the American College of Cardiology in 2023 found that one-year adherence rates for injectable PCSK9 inhibitors among commercially insured patients ranged between 40 and 55 percent, depending on the condition being treated and the patient population. Adherence to oral statins in the same patient populations runs at 60 to 75 percent over the same period. An oral PCSK9 inhibitor would be expected to track closer to the statin adherence pattern, which over a population of millions of high-risk patients represents a substantial difference in cardiovascular outcomes.

How enlicitide compares to inclisiran, another oral alternative in development

Enlicitide is not the only drug trying to expand the oral cholesterol treatment market. Inclisiran, developed by Novartis, works through a different mechanism using small interfering RNA to reduce PCSK9 production in liver cells rather than blocking the protein directly. Inclisiran is currently approved as an injection given twice yearly. An oral formulation has been in development, but Novartis's oral inclisiran program has faced delivery challenges similar to those that slowed enlicitide's earlier iterations.

Separately, MSD, which markets the drug as Merck in the United States, has been developing oral MK-0616, another oral PCSK9 inhibitor that produced LDL reductions of approximately 55 percent in its phase two results published in the Journal of the American College of Cardiology in 2023. Enlicitide's 60 percent reduction result is slightly higher, though cross-trial comparisons carry the usual caveats about different patient populations and trial designs.

What happens next for enlicitide

The trial results were presented at a major cardiology conference and submitted for peer-reviewed publication. The drug's developer is expected to hold an end-of-phase two meeting with the FDA to discuss the design requirements for a phase three program. Phase three for a cardiovascular drug of this type typically involves thousands of patients followed for two to four years to establish both safety at scale and cardiovascular outcome benefits.

If phase three begins in late 2025 or early 2026 and runs for three years, an FDA submission would realistically arrive no earlier than 2029. That timeline assumes no major safety signals emerge and that the cardiovascular outcomes data supports the efficacy seen in earlier trials. The drug would then face the standard pricing and access negotiations with insurers that have slowed adoption of the injectable PCSK9 inhibitors, though an oral formulation's manufacturing cost profile may make favorable pricing more achievable.